Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.57 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.57 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14123937 | 0.94 | HSP90AB1 (0.64) | HSP90AB1HSP90AA1HSP90B1TRAP1NPC1 | |
| SCHEMBL16107375 | 0.92 | HSP90AB1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL12391441 | 0.89 | HSP90AB1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL12047274 | 0.88 | HSP90AB1 (0.63) | HSP90AB1HSP90AA1HSP90B1TRAP1NPC1 | |
| SCHEMBL12368070 | 0.88 | HSP90AB1 (0.63) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL2263981 | 0.83 | HSP90AA1 (0.61) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL12060302 | 0.82 | HSP90AB1 (0.66) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL14123932 | 0.79 | HSP90AA1 (0.66) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL4566998 | 0.78 | HSP90AB1 (0.49) | HSP90AB1HSP90AA1HSP90B1TRAP1NPC1 | |
| SCHEMBL28567205 | 0.78 | NPC1 (0.51) | HSP90AB1HSP90AA1HSP90B1TRAP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9120745-B2 | Triazole compounds that modualte HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2014-10-02 | — | — | US | disclosed |
| US-8742133-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| EP-2193135-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | Synta Pharmaceuticals Corp. (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009023211-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AB1 1/4885HSP90AA1 3/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.